Loading company financials…
Nasdaq · Biological Products, (No Diagnostic Substances) · CIK 0000842023
$72.43
+0.11% · delayed 15 min
$11.31B market value
What this company does
BIO-TECHNE develops and makes medicines. It took in $1.22B last year, which makes it a mid-sized company. Of every dollar it sells, about 15 cents is left as profit.
Financial health
Generally healthy, with a few things to watch.
From BIO-TECHNE Corp's FY2026 annual filing · share price scored separately
Every check behind the three models, and what each one tests
Measured against FY2025, from the 10-K
Improved: +147.8%
$73.4M to $181.9M
Improved: +8.9 pts
6.0% to 15.0%
Improved: +63.2%
$162.2M to $264.7M
It makes a profit rather than burning through money.
$181.9M earned last year
Day-to-day operations generate real cash, not just accounting profit.
$292.1M cash from operations
It passes almost every standard check of financial strength.
Piotroski 7/8
A widely used bankruptcy-risk model places it well clear of distress.
Altman Z 15.86
Sales are shrinking rather than growing.
down 0.4% on last year
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 15% a year for the next 10 years. Over the last 10 years it grew by about 8% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 15 cents of every dollar of sales as profit, earning $181.9M last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Whether the dividend is covered by what the business actually earns
It pays out 27 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 17% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2026 annual filing
Last year it earned $181.9M and generated $292.1M of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Annual report(10-K) | 2026-08-24 | 2026-06-30 |
| Major event announcement(8-K) | 2026-08-12 | 2026-08-12 |
Financial figures are from TECH's 10-K for fiscal year 2026 (period ending 2026-06-30), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
7 of 8 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. One could not be evaluated and is excluded from the total rather than counted as a failure.
15.86
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2026 filing as filed with the SEC.
Changed: -7.0%
$31.0M to $28.9M
4 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 13% and 18%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 4.1% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
No. Sales shrank 0.4% last year.
It does not appear so. For every $1 it owes, it owns $5.41 in assets.
Expensive. Investors pay $62.2 for every $1 of yearly profit, so a lot of future growth is already priced in.
This company has not reported enough of the required figures to calculate this score.
At a glance
| Major event announcement(8-K) | 2026-06-26 | 2026-06-23 |
| Major event announcement(8-K) | 2026-06-25 | 2026-06-25 |
| Quarterly report(10-Q) | 2026-05-06 | 2026-03-31 |
| Major event announcement(8-K) | 2026-05-06 | 2026-05-06 |
| Major event announcement(8-K) | 2026-02-11 | 2026-02-09 |
| Quarterly report(10-Q) | 2026-02-04 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-04 | 2026-02-04 |
| Quarterly report(10-Q) | 2025-11-05 | 2025-09-30 |
| Major event announcement(8-K) | 2025-11-05 | 2025-10-30 |
| Shareholder voting information(DEF 14A) | 2025-09-19 | 2025-10-30 |
| Annual report(10-K) | 2025-08-22 | 2025-06-30 |
| Major event announcement(8-K) | 2025-08-06 | 2025-08-06 |
| Quarterly report(10-Q) | 2025-05-08 | 2025-03-31 |
| Major event announcement(8-K) | 2025-05-07 | 2025-05-07 |
| Major event announcement(8-K) | 2025-05-06 | 2025-04-30 |
| Major event announcement(8-K) | 2025-03-04 | 2025-02-26 |
| Quarterly report(10-Q) | 2025-02-06 | 2024-12-31 |
| Major event announcement(8-K) | 2025-02-05 | 2025-01-30 |
Coverage from the last 30 days
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Yahoo Finance ·
Winners And Losers Of Q2: Bio-Techne (NASDAQ:TECH) Vs The Rest Of The Research Tools & Consumables Stocks
Yahoo Finance ·
Bio-Techne Corrects Dividend Announcement
Yahoo Finance ·
Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales
Yahoo Finance ·
Bio-Techne Declares Dividend
Yahoo Finance ·
Is Bio-Techne (TECH) Above Fair Value After A 44% Return?
Yahoo Finance ·
Investors’ Confidence in Bio-Techne Corp. (TECH) Strengthens as Headwind Eases
Yahoo Finance ·
Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?
Yahoo Finance ·
1 Surging Stock for Long-Term Investors and 2 That Underwhelm
Yahoo Finance ·
1 Profitable Stock to Own for Decades and 2 We Turn Down
Yahoo Finance ·
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
Yahoo Finance ·
Is Wall Street Bullish or Bearish on Bio-Techne Stock?
Yahoo Finance ·
Primary sources and further research